Melanoma Vaccines Mixed Past, Promising Future

Surgical Clinics of North America

Volumn 94, Issue 5, 2014, Pages 1017-1030

  Ozao Choy, Junko ^a   Lee, Delphine J ^a   Faries, Mark B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; Immunomodulator; Immunotherapy; Melanoma; Vaccine

Indexed keywords

GANGLIOSIDE GM2; GLYCOPROTEIN GP 96; IMMUNOMODULATING AGENT; MELANOMA VACCINE; PEPTIDE VACCINE; PLACEBO; TALIMOGENE LAHERPAREPVEC; TUMOR ANTIGEN; ADJUVANT; CANCER VACCINE; GANGLIOSIDE; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; SUBUNIT VACCINE; VACCINE;

ANTIGEN EXPRESSION; CANCER IMMUNIZATION; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MELANOMA; MELANOMA CELL LINE; MYCOBACTERIUM BOVIS BCG; REVIEW; FORECASTING; IMMUNOLOGY; METHODOLOGY; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TUMOR;

ADJUVANT; IMMUNOMODULATOR; IMMUNOTHERAPY; MELANOMA; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; FORECASTING; GANGLIOSIDES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MELANOMA; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; VACCINES, SUBUNIT;

EID: 84907667325     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.07.005     Document Type: Review

References (51)

1. Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases 1893, Lea Brothers, New York.
2. Coley W. Treatment of inoperable malignant tumors with the toxins of erysipelas and the bacillus prodigiosus. Trans Am Surg Assoc 1894, 12:183.
3. McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006, 26:154-158.
4. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. NEngl J Med 2010, 363(5):411-422.
5. Cheever M.A., Higano C.S. PROVENGE (Sipuleucel-T) in prostate cancer: the firstFDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011, 17(11):3520-3526.
6. Schwartzentruber D.J., Lawson D.H., Richards J.M., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. NEngl J Med 2011, 364(22):2119-2127.
7. Schwartz R.S. Paul Ehrlich's magic bullets. NEngl J Med 2004, 350(11):1079-1080.
8. Harbst K., Lauss M., Cirenajwis H., et al. Molecular and genetic diversity in the metastatic process of melanoma. JPathol 2014, 233(1):39-50.
9. Tosti G., di Pietro A., Ferrucci P.F., et al. HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. Expert Rev Vaccines 2009, 8(11):1513-1526.
10. Testori A., Richards J., Whitman E., et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. JClin Oncol 2008, 26(6):955-962.
11. Tosti G., Cocorocchio E., Pennacchioli E., et al. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opin Biol Ther 2014, 14(7):955-967.
12. Berd D., Sato T., Maguire H., et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. JClin Oncol 2004, 22(3):403-415.
13. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2002, 2(3):335-342.
14. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 2004, 3(5):521-527.
15. Dillman R.O., Nayak S.K., Barth N.M., et al. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer Biother Radiopharm 1998, 13(3):165-176.
16. Dillman R., Selvan S., Schiltz P., et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm 2004, 19(5):658-665.
17. Hersey P., Coates A., McCarthy W., et al. Adjuvant immunotherapy of patients withhigh-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. JClin Oncol 2002, 20:4148-4190.
18. Suriano R., Rajoria S., George A.L., et al. Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma. Mol Clin Oncol 2013, 1(3):466-472.
19. Sondak V., Liu P., Tuthill R., et al. Adjuvant immunotherapy or resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. JClin Oncol 2002, 20:2058-2066.
20. Sosman J., Unger J., Liu P., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. JClin Oncol 2002, 20(8):2067-2075.
21. Morton D., Hsueh E., Essner R., et al. Prolonged survival in patients receiving active immunotherapy with Canvaxin therapeutic vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002, 236(4):438-448.
22. Morton D.L., Mozzillo N., Thompson J.F., et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after compete resection of melanoma metastatic to regional or distant sites. JClin Oncol 2007, 25(18S). [abstract: 8508].
23. Morton D., Mozzillo N., Thompson J., et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin), compared to placebo as post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 2006, 13(Suppl 2):5s.
24. Morton D., Ravindranath M., Irie R. Tumor gangliosides as targets for active specific immunotherapies of melanoma in man. Progress in brain research 1994, vol. 104:251-275. Elsevier, Amsterdam.
25. Kirkwood J., Ibrahim J., Sosman J., et al. High-dose interferon alpha 2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. JClin Oncol 2001, 19:2370.
26. Eggermont A.M., Suciu S., Rutkowski P., et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor>1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. JClin Oncol 2013, 31(30):3831-3837.
27. van der Bruggen P., Traversari C., Chomez P., et al. Agene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254(5038):1643-1647.
28. Rosenberg S., Yang J., Schwartzentruber D., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4(3):321-327.
29. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363(8):711-723.
30. Lawson D.H., Lee S.J., Tarhini A.A., et al. E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. JClin Oncol 2010, 28(Suppl 15). [abstract: 8504].
31. Slingluff C.L., Petroni G.R., Chianese-Bullock K.A., et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. JClin Oncol 2011, 29(21):2924-2932.
32. Rosenberg S., Yang J., Schwartzentruber D., et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. JImmunol 1999, 163:1690-1695.
33. Slingluff C.L. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?. Cancer J 2011, 17(5):343-350.
34. Faries M.B., Czerniecki B.J. Dendritic cells in melanoma immunotherapy. Curr Treat Options Oncol 2005, 6(3):175-184.
35. Nestle F., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4(3):269-270.
36. Schadendorf D., Nestle F., Broecker E., et al. Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells as first-line treatment ofpatients with metastatic melanoma: results of a prospective-randomized phase III study. American Society of Clinical Oncology 2004, vol. 23:709. American Society of Clinical Oncology, New Orleans (LA).
37. Zhou F., Ciric B., Zhang G.X., et al. Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressiveIL-10(+) IFN-gamma(+)-producing CD4(+) T cells. Immunol Res 2013, 56(1):1-8.
38. Palucka A.K., Ueno H., Connolly J., et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. JImmunother 2006, 29(5):545-557.
39. Morton D., Eilber F., Holmes E., et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974, 180(4):635-643.
40. Sopkova B., Kolar V. Intralesional BCG application in malignant melanoma. Neoplasma 1976, 23(4):421-426.
41. Mastrangelo M., Bellet R., Berkelhammer J., et al. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 1975, 36(4):1305-1308.
42. McKhann C.F., Hendrickson C.G., Spitler L.E., et al. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection. Cancer 1975, 35(2):514-520.
43. Sparks F., Silverstein M., Hunt J., et al. Complications of BCG immunotherapy in patients with cancer. NEngl J Med 1973, 289:827-830.
44. Coit D.G., Andtbacka R., Anker C.J., et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. JNatl Compr Canc Netw 2013, 11(4):395-407.
45. Kidner T.B., Morton D.L., Lee D.J., et al. Combined intralesional bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. JImmunother 2012, 35(9):716-720.
46. Hiniker S.M., Chen D.S., Knox S.J. Abscopal effect in a patient with melanoma. NEngl J Med 2012, 366(21):2035. [author reply: 2035-6].
47. Kaufman H.L., Bines S.D. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010, 6(6):941-949.
48. Senzer N.N., Kaufman H.L., Amatruda T., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. JClin Oncol 2009, 27(34):5763-5771.
49. Kaufman H.L., Kim D.W., DeRaffele G., et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2009, 17(3):718-730.
50. Andtbacka R., Collichio F.A., Amatruda T., et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. JClin Oncol 2013, 31(Suppl). [abstract: 9008].
51. Faries M.B., Hsueh E.C., Ye X., et al. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 2009, 15(22):7029-7035.